Prolonged molecular control during intermittent reduced-intensity blinatumomab maintenance in a transplant-ineligible patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia and IKZF1 deletion.

Blincyto (blinatumomab) - Amgen

Intron A (interferon α-2b) - Merck (MSD), Biogen

dasatinib - Generic mfg.

Prolonged molecular control during intermittent reduced-intensity blinatumomab maintenance in a transplant-ineligible patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia and IKZF1 deletion. (PubMed, Clin Transl Immunology) - Sep 24, 2026 - "A 64-year-old man with Ph+ ALL harbouring a heterozygous IKZF1 deletion relapsed while receiving dasatinib, with emergence of an ABL1 E255K/V mutation...Intermittent reduced-intensity blinatumomab maintenance guided by serial MRD monitoring was feasible and associated with durable molecular control in a transplant-ineligible patient with high-risk Ph+ ALL. This strategy merits prospective evaluation."
Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • ABL1 • CD8 • IKZF1

http://www.ncbi.nlm.nih.gov/pubmed/42774342

Jinjun Yang; Shuwen Guo; Xiaoqian Duan; Yu Wu; Yufei Yang

Sep 24, 2026